GSK-1070806
As of the edition of 20 October 2026, GSK-1070806 is a drug: in active development; acts on IL18.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 9, 3 stopped early
- Disease areas
- Inherited and neonatal; Skin and connective tissue; Immune system; Digestive system; Eye; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL18 | Interleukin-18 | Q14116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 5 | 1 | 0 | 3 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2010 to now |